BCC 2021 | Metaplastic vs. TNBC: comparing long-term outcomes

Antonia Girardi, MD, Istituto Europeo di Oncologia, Milan, Italy, discusses the results of a retrospective analysis evaluating treatment of patients with metaplastic breast carcinoma and comparing survival and prognosis to a matched population of patients with triple-negative breast cancer (TNBC). In this study, it was determined that metaplastic and ductal breast cancers with a triple-negative phenotype show similar overall and disease-free survival. Metaplastic cancers respond poorly to neoadjuvant treatment, and in the absence of novel targeted therapies, surgical treatment remains the first choice. This interview took place during the 17th St. Gallen International Breast Cancer Conference.